Neogen Corporation (NEOG) is facing challenges from global macroeconomic issues impacting its international business. Despite some growth in specific product lines, the company is navigating a tough competitive landscape and rising costs. While Neogen is making progress in key markets, its stock carries a Zacks Rank #4 (Sell). This article analyzes the factors affecting Neogen’s performance and explores alternative investment options in the medical space.
